Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 306

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

Open access
Isenberg, David, Gordon, Caroline, Licu, Daiana, Copt, Samuel, Rossi, Claudia Pena, Wofsy, David, Babini, A, Lazaro, M, Lucero, E, Merono, C, Rillo, O, Spindler, A, Tate, G, Velasco Zamora, B, Bossingham, D, Littlejohn, G, Nicholls, D, Reeves, G, Rischmueller, M, Zamani, O, Sato, E, Scheinberg, M, Zerbini, C, Rashkov, R, Glasnovic, M, Martinovic-Kaliterna, D, Morovic-Vergles, J, Novak, S, Tegzova, D, Vavrincova, P, Amoura, Z, Carle, P, Hachulla, E, Jorgensen, C, Sibilia, J, Viallard, J, Braun, J, Hiepe, F, Kuhn, A, Lorenz, H, Schmidt, R, Schulze-Koops, H, Wacker, J, Settas, L, Mouli Veeravalli, S, Balbir-Gurman, A, Langevitz, P, Mevorach, D, Molad, Y, Bae, S, Cho, CS, Kim, HY, Suh, C, Andersone, D, Ziade, N, Baranauskaite, A, Stropuviene, S, Gun, S, Kong, N, Sulaiman, W, Ramos Remus, C, Saldate Alonso, C, Huizinga, T, Tak, P, van Paassen, P, Arroyo, C, Gomez, H, Perez, E, Ramiterre, E, Salido, E, Brzosko, M, Chudzik, D, Dyczek, A, Jeka, S, Sierakowski, S, Zdrojewski, Z, Barbarash, O, Ershova, O, Gordienko, A, Lomareva, N, Shvarts, Y, Sorotskaya, V, Vezikova, N, Yakushin, S, Bogic, M, Dimic, A, Damjanov, N, Petrovic, R, Stojanovic, L, Kalla, A, Louw, I, Nayiager, S, Reuter, H, Spargo, C, Whitelaw, D, Carbonell Abello, J, Fernandez Nebro, A, Gomez Reino, J, Lopez Longo, F, von Kempis, J, Huang, CM, Lan, JL, Lin, HY, Liou, LB, Bruce, I, Tahir, H, Abrahamovych, O, Dyadyk, O, Nikirenkov, Y, Rudyk, Y, Smiyan, S, Stanislavchuk, M, Ter-Vartanyan, S, Aranow, C, Askanase, A, Chakravarty, E, Chatham, W, Clark, M, Dhar, P, Dikranian, A, Fiechtner, J, Ginzler, E, Harmon, C, Knibbe, W, Lee, E, Lockshin, M, Luggen, M, Massarotti, E, Mitri, G, Peng, S, Singer, N·2015·Annals of the Rheumatic Diseases

Abstract

OBJECTIVES: Despite advances in systemic lupus erythematosus (SLE) treatment, many patients suffer from the disease and side effects. Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferation-inducing ligand, which are increased in patients with SLE. METHODS: In this double-blind, placebo-controlled study, patients with moderate-to-severe SLE were randomised to atacicept 75 mg or atacicept 150 mg administered subcutaneously, or placebo twice-weekly for 4 weeks, then weekly for 48 weeks. Primary and secondary efficacy measures were the proportion of patients experiencing at least one flare of British Isles Lupus Assessment Group A or B, and time to first flare, respectively. RESULTS: Enrolment in the atacicept 150 mg arm was discontinued prematurely due to two deaths. In the intention-to-treat population (n=461), there was no difference in flare rates or time to first flare between atacicept 75 mg and placebo. Analysis of patients treated with atacicept 150 mg suggested beneficial effect versus placebo in flare rates (OR: 0.48, p=0.002) and time to first flare (HR: 0.56, p=0.009). Both atacicept doses were associated with reductions in total Ig levels and anti-dsDNA antibodies, and increases in C3 and C4 levels. Most treatment-emergent adverse events were mild or moderate. CONCLUSIONS: There was no difference between atacicept 75 mg and placebo for flare rate or time to first flare. Analysis of atacicept 150 mg suggested benefit. TRIAL REGISTRATION NUMBER: EudraCT: 2007-003698-13; NCT00624338.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2013-205067

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 306

Metadata

Authors
Isenberg, D., Gordon, C., Licu, D., Copt, S., Rossi, C. P., Wofsy, D., Babini, A., Lazaro, M., Lucero, E., Merono, C., Rillo, O., Spindler, A., Tate, G., Velasco Zamora, B., Bossingham, D., Littlejohn, G., Nicholls, D., Reeves, G., Rischmueller, M., Zamani, O., Sato, E., Scheinberg, M., Zerbini, C., Rashkov, R., Glasnovic, M., Martinovic-Kaliterna, D., Morovic-Vergles, J., Novak, S., Tegzova, D., Vavrincova, P., Amoura, Z., Carle, P., Hachulla, E., Jorgensen, C., Sibilia, J., Viallard, J., Braun, J., Hiepe, F., Kuhn, A., Lorenz, H., Schmidt, R., Schulze-Koops, H., Wacker, J., Settas, L., Mouli Veeravalli, S., Balbir-Gurman, A., Langevitz, P., Mevorach, D., Molad, Y., Bae, S., Cho, C., Kim, H., Suh, C., Andersone, D., Ziade, N., Baranauskaite, A., Stropuviene, S., Gun, S., Kong, N., Sulaiman, W., Ramos Remus, C., Saldate Alonso, C., Huizinga, T., Tak, P., van Paassen, P., Arroyo, C., Gomez, H., Perez, E., Ramiterre, E., Salido, E., Brzosko, M., Chudzik, D., Dyczek, A., Jeka, S., Sierakowski, S., Zdrojewski, Z., Barbarash, O., Ershova, O., Gordienko, A., Lomareva, N., Shvarts, Y., Sorotskaya, V, Vezikova, N., Yakushin, S., Bogic, M., Dimic, A., Damjanov, N., Petrovic, R., Stojanovic, L., Kalla, A., Louw, I., Nayiager, S., Reuter, H., Spargo, C., Whitelaw, D., Carbonell Abello, J., Fernandez Nebro, A., Gomez Reino, J., Lopez Longo, F., von Kempis, J., Huang, C., Lan, J., Lin, H., Liou, L., Bruce, I., Tahir, H., Abrahamovych, O., Dyadyk, O., Nikirenkov, Y., Rudyk, Y., Smiyan, S., Stanislavchuk, M., Ter-Vartanyan, S., Aranow, C., Askanase, A., Chakravarty, E., Chatham, W., Clark, M., Dhar, P., Dikranian, A., Fiechtner, J., Ginzler, E., Harmon, C., Knibbe, W., Lee, E., Lockshin, M., Luggen, M., Massarotti, E., Mitri, G., Peng, S., & Singer, N.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2015-11
Volume
74
Issue
11
Pages
2006-2015
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2154831555
Cited by
306
References
18
FWCI
28.51
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). https://app.cochat.ai/papers/10.1136/annrheumdis-2013-205067
The paper
Isenberg, D., Gordon, C., Licu, D., Copt, S., Rossi, C. P., Wofsy, D., Babini, A., Lazaro, M., Lucero, E., Merono, C., Rillo, O., Spindler, A., Tate, G., Velasco Zamora, B., Bossingham, D., Littlejohn, G., Nicholls, D., Reeves, G., Rischmueller, M., . . . Singer, N. (2015). Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2013-205067

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.